Thursday, June 03, 2021 7:56:44 AM
Thu, June 3, 2021
-- EYSUVIS Added to OptumRx Commercial Formularies Effective May 21, 2021 --
-- Expands Total Commercial Coverage for EYSUVIS to More Than 88 Million Lives --
Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021.
"We are pleased to announce the addition of EYSUVIS to OptumRx’s commercial formularies, which represents a significant milestone towards our goal of ensuring broad market access," said Todd Bazemore, Chief Operating Officer of Kala Pharmaceuticals. "More than 88 million people with commercial health insurance now have access to EYSUVIS. We anticipate this figure will continue to grow from our ongoing efforts with Commercial and Medicare Part D health plans, as we work towards our ultimate goal of delivering broad payer coverage for EYSUVIS to the millions of people in the United States who suffer from dry eye disease."
EYSUVIS was approved by the U.S. Food and Drug Administration (FDA) in October 2020 as the first and only prescription therapy indicated specifically for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Kala commenced the promotional launch of EYSUVIS in the United States in January 2021. EYSUVIS is available through both national and regional U.S. pharmaceutical distribution centers, as well as local retail pharmacies or home delivery.
Recent KALA News
- KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:19 PM
- KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 06:09:11 PM
- KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/19/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:07:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:06:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:04:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:03:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 01:22:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 01:05:17 PM
- KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2023 01:00:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/18/2023 08:04:57 PM
- KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/20/2023 08:01:00 PM
- KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/04/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2023 08:01:10 PM
- KALA BIO to Participate in Upcoming Investor Conferences in August • GlobeNewswire Inc. • 08/02/2023 08:01:00 PM
- Kala Pharmaceuticals Announces Name Change to KALA BIO • GlobeNewswire Inc. • 08/02/2023 12:00:00 PM
- Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/19/2023 08:01:00 PM
- Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/23/2023 08:01:00 PM
- Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference • GlobeNewswire Inc. • 06/02/2023 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM